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INTRODUCTION
Cellular immunity is the most important part of the immune
system in anticancer immune response. Numerous innate
and adaptive immune effector cells and molecules partici-
pate in the recognition and destruction of cancer cells, a
process that is known as cancer immunosurveilance. How-
ever, cancer cells avoid such immunosurveilance through
the outgrowth of poorly immunogenic tumour cell variants,
called immunoselection, and through suppression of the im-
mune system (Zitvogel et al., 2006). Cancer-associated im-
munosuppression is mediated by evaluation of an immuno-
suppressive network that extends from the primary tumour
site to secondary lymphoid organs and peripheral blood im-
munocompetent cells. Chronic stimulation of T cells by tu-
mours leads to activation-induced cell death and insuffi-
ciency of cellular immune response.
It could be expected that each additional immunosuppres-
sive factor contributes to the tumour escaping from immu-
nological control and promotes cancer growth.
Human herpes viruses (HHV) are frequently present in pa-
tients with a compromised immune system and are de-
scribed as immunotropic viruses that can infect several cells
implicated in the generation of both cell-mediated and hu-
moral immune response. Beta-herpes viruses HHV-6 and
HHV-7 have some similar biological properties and both vi-
ruses are often recognised concomitantly, suggesting that
viral syndromes may often be due to a combination of these
viruses (Hall et al., 2006). HHV-6 and HHV-7 can induce
immunosuppression by various mechanisms and triggering
of apoptosis in lymphocytes is one of the most important
(Mirrandola et al., 2006).
CD4+ T lymphocytes appear to be the preferential target for
replication of HHV-6 as well as HHV-7 viruses in vivo. In
addition, CD8+ T cells, monocytes/macrophages, natural
killer (NK) cells, epithelial, endothelial, neural cells and
fibroblasts may be infected (Clark, 2002; Dockrell, 2003;
De Boele et al., 2005; Miyjake et al., 2006).
An effective CD4+ T cells response is believed to prevent
tolerance induction by effective function of tumour antigen
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CD4+ T lymphocytes appear to be the preferential target for replication of HHV-6 (human herpes
virus) as well as HHV-7 viruses in vivo. In addition, CD8+ T cells, monocytes/macrophages, natu-
ral killer cells, epithelial, endothelial, neural cells and fibroblasts may be infected. By definition,
however, even a tumour designated by pathologists to be early stage may be late stage when
considered by the immune system. Certainly, even early stage tumours have evaded immune
control, suggesting that they have acquired many immunosuppressive characteristics. The aim of
the study was to clarify the influence of beta-herpes viruses on cellular immune response. In 95
gastrointestinal cancer patients we determined the immunocompetent cell level CD3, CD4, CD8,
CD19, CD38, CD95, CD25 using laser flow cytofluorimeter and B- herpes viruses HHV-6, HHV-7
presence using a nested polymerase chain reaction method. Our data showed no statistically sig-
nificant difference in immunocompetent cell level between negative, latent and active HHV-6,
HHV-7 infection. Patients with immunocompromised immune status (lymphopenia) had a ten-
dency to decreased CD4+, CD19+ absolute count. It may be suggested that virus-mediated im-
mune response inhibition seems to be similar to cancer mediated, but differences in immune
response among the same group of individuals had no influence on the average number of the
immunocompetent cells in the group. Therefore, to characterise host-virus-tumour interactions, in-
dividual interpretation of each case is needed.
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on cytotoxic CD8+ T cells, thereby preventing tumour es-
cape from immunological control. Lack of CD4+ T cells
help is also involved in the deletion of cytotoxic T Ly in the
chronic viral infection. The persistent presence of low levels
of antigens in these cases is similar to some cancers. There-
fore, it is possible that cytotoxic T Ly against tumour anti-
gens are deleted when T helper responses are absent (Ken-
nedy and Celis 2006). Induction of T cells apoptosis by
viruses is one of the mechanisms to destroy host immune
system. Based on previous studies, it is known that resting
T cells are not susceptible to Fas (CD95)-dependent apopto-
sis, but Fas-triggered T cells death happens in activated ef-
fector T cells upon encountering their antigens. Thus, active
effector T cells will be eliminated and less active or sup-
pressed T cells (CD95-) will be preserved (Lenardo, 1991;
Russell et al., 1991).
Beta-herpes viruses frequently reactivated under immuno-
suppressive conditions, and reactivation of HHV-6 plays a
significant pathologic role in immunocompromissed pa-
tients. The pathogenic significance of HHV-7 reactivation
remains uncertain, however, indirect effects of HHV-7 rep-
lication may include interactions between HHV-6 and -7,
and the development of cytomegalovirus disease (Smith et
al., 2001; Moussa et al., 2002).
By modulating specific antiviral immune response, beta-
herpes viruses can facilitate their own spread and persis-
tence in vivo as well as contribute to the pathogenic effect
of the other agents (Lusso, 2006). The risk of reactivation of
HHV-6 and HHV-7 in different conditions of immunosup-
pressions has been clearly showed, and clinical attention
should be paid to immunocompromissed patients with reac-
tivated and persistently active HHV-6, HHV-7 infections at
later ages (Cassula et al., 2001). HHV-6 and HHV-7 are fre-
quently present in patients with various lymphoproliferative
disorders including multiple mieloma, Hodgkin’s disease,
T-cell lymphoma and myeloproliferative syndromes. Addi-
tionally, HHV-6 has been linked to precancerous lesions of
the uterine cervix (Tran-Thanh et al., 2002). Immuno-
modulating processes between host and virus during HHV-6
and HHV-7 infection in solid tumour patients were not
widely investigated.
The interactions between beta-herpes viruses and the im-
mune system have been extensively characterised using in
vitro and ex vivo models while in vivo studies are still lim-
ited, as concluded by Lusso (2006).
Our aim was to clarify the influence of beta-herpes viruses
on cellular immune response in gastrointestinal (GI) can-
cer patients before any antitumour treatment.
MATERIALS AND METHODS
We examined 95 gastrointestinal (GI) cancer patients before
antitumour treatment. Patient age was from 38 to 75 years.
Patients were divided into two groups according to lympho-
cyte count in peripheral blood: Ly > 1400 per 1 mm3 and
Ly < 1400 1 mm3 (group I and II, respectively). HHV-6 and
HHV-7 were detected in both groups. Lymphocyte sub-
populations were determined by a laser flow cytofluori-
meter Becton Dickenson with corresponding monoclonal
antibodies to CD3+, CD4+, CD8+, CD16+, CD19+, CD38+,
CD25+, CD95+ lymphocytes. Nested polymerase chain re-
action (nPCR) was used for the identification of viral se-
quences in DNA isolated from peripheral blood leukocytes
(PBL) and plasma (markers of latent/persistent and active
infection, respectively). Total DNA was isolated from 0.5
ml of fresh whole blood by phenol-chloroform extraction,
QIAamp DNA Blood Kit (Qiagen) was used for DNA puri-
fication from 200 l of cell free blood plasma. The plasma
samples were treated with Deoxyribonuclease I before
DNA purification. To assure the quality of the PBLs DNA
as well as exclude contamination of plasma DNA by cellu-
lar DNA, a globin PCR was performed. PCR amplification
for the viruses was carried out in the presence of 1 g of
PBL DNA and 10 l of plasma DNA (corresponding to 100
l of plasma). The detection of HHV-6, HHV-7 and CMV
DNA was performed according to Secchiero et al. (1995)
Berneman et al. (1992), and Studahl et al. (1995), respec-
tively. Positive (virus genomic DNA) and negative (DNA
without virus-specific sequences) and water controls were
included in each experiment.
The investigation was carried out with approval of Ethics
Committee of Rîga Stradiòð University and all patients gave
their informed consent prior to the examination.
As statistical method, Fisher’s exact test, NPar, Kruskal
Walles test for statistical evolution of the results were used.
RESULTS
Patient distribution with HHV-6, HHV-7 is shown in Table
1. There was no statistically significant difference between
leukocyte, lymphocyte, monocyte, neutrophile and CD3,
CD4, CD8, CD38, CD16, CD19, CD95, CD25 cell abso-
lute counts and CD4/CD8 ratio between negative, latent and
active HHV6 and HHV7 infection groups in GI cancer pa-
tients (Table 2). However, we observed a tendency that the
number of CD3+, CD4+, CD8+, CD38+ and CD95+ cells
increased in peripheral blood in GI cancer patients with ac-
tive beta-herpes virus infection. It was surprising that the to-
tal count of CD16+ cells was not influenced by virus infec-
tion in our patients. Average count of the determined
parameters in patients with Ly > 1,400 (group I) and pa-
T a b l e 1
HHV-6 AND HHV-7 IN GASTROINTESTINAL CANCER PATIENTS
Infection stage HHV-6 HHV-7 HHV-6/HHV-7
n of patients (%) n of patients (%) n of patients (%)
Negative 83 (87.4) 33 (34.7) 32 (33.7)
Latent 11 (11.6) 39 (41.1) 39 (41.1)
Active 1 (1.1) 23 (24.2) 24 (25.3)
HHV, human herpes virus
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tients with Ly < 1,400 (group II) are shown in tables 3 and
4, respectively.
Cellular immune parameters were determined in both
immunocompetent (Ly > 1,400) and immunocompromised
(Ly < 1,400) GI cancer patients groups, independently of
beta-herpes virus infection. Number of T cells and NK cells
was higher in patients without lymphopenia, as expected,
while the total count of B cells and CD25+ cells was similar
in both groups (Table 5).
Comparative analysis of Ly subsets between groups I and II
was performed. Each group was subdivided into non in-
fected, latent and active HHV-6 and HHV-7 infected patient
subgroups. Patients with a normal Ly count (group I) and
active viral infection tended to have increased counts of
CD3+, CD4+, CD8+, CD19+ and CD95+ cells (Table 3).
The number of CD4+ T as well as CD19+ B cells in the pa-
tients with a lower Ly count (group II) and active HHV-6,
HHV-7 infection tended to be lower (Table 4).
GI cancer patients with latent HHV-6, HHV-7 infection had
the highest number of CD25+ T cells and the lowest
number of CD4+ T cells among patients in group I; how-
ever, a significant difference in absolute counts of immuno-
competent cells was not observed (Table 4). In contrast with
group I, immunocompromised patients (group II) had the
highest number of CD4+ T cells and the lowest number of
CD25+ T cells between subgroups. There was no signifi-
cant difference between negative, latent and active HHV-6,
HHV-7 infection subgroups in both immunocompetent and
immunocompromised GI cancer patients groups.
Different immune response was observed among patients in
the same subgroup. Average count of Ly subsets in each of
the patients did not reflect individual immune response and
intensity of cellular immune reactions.
DISCUSSION
Despite immune response HHV-6, HHV-7 viruses are never
completely eradicated from the host. A key feature of both
viruses life-style in the human host is their ability to infect
T a b l e 2
ABSOLUTE COUNT (MEAN ± SD) OF LYMPHOCYTE SUB-











































































HHV, human herpes virus; Ly, lymphocyte; Mo, monocyte
T a b l e 3
COUNT (MEAN ± SD) OF IMMUNOCOMPETENT CELLS IN GI




































































HHV, human herpes virus; GI, gastrointestinal; Ly, lymphocyte; Mo,
monocyte
T a b l e 4
COUNT (MEAN ± SD) OF IMMUNOCOMPETENT CELLS IN GI




































































HHV, human herpes virus; GI, gastrointestinal; Ly, lymphocyte; Mo,
monocyte
T a b l e 5
ABSOLUTE COUNT (MEAN ± SD) OF IMMUNOCOMPETENT






L 7140 ± 2044 5360 ± 1962 < 0.001 *
Mo
587± 199 460 ± 190
< 0.05 *
CD3
1545 ± 523 802 ± 209
< 0.001*
CD4
854 ± 299 443 ± 169
< 0.001 *
CD8
665 ± 386 369 ± 151
< 0.001 *
CD38
609 ± 248 318 ± 105
< 0.001 *
CD 16
407 ± 266 209 ± 129
< 0.001 *
CD19
175 ± 19 117 ± 115
0.31
CD95
1086 ± 394 556 ± 165
< 0.001*
CD25 170 ± 146 95 ± 49 0,09
GI, gastrointestinal; * P < 0.05; Ly, lymphocyte; Mo, monocyte
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and survive, in a latent/persistent form, in the cells of the
immune system. Modulation of functional properties of host
immune factors is an important mechanism of evading the
immune response or creating an environment in which the
virus can survive (Clark, 2000; Dockrell, 2003). Our results
show that patients with latent and active infection in com-
parison to negative had tendency to have higher number of
CD3+, CD4+, CD8+, CD95+ cells. It may be explained by
additional activation of immune cells due to viral infection.
In beta-herpes viruses-infected patients persistent immune
activation driven by constant supply of HHV-6 and HHV-7
antigens in chronic or latent infection was observed (Wang
et al., 2006). In comparison, our data showed that patients
with latent infection had in average higher CD3, CD4, CD8,
CD38, CD95, CD25 absolute count than patients with nega-
tive HHV-6 and HHV-7 infection.
Reduced Th1 immune response was observed in HHV-6 in-
fected individuals (Morel et al., 1998). We did not observe
Th1 immune answer depression in our active, latent infec-
tion group. By definition, however, even tumour designated
by pathologists to be early stage may be late stage when
considered by the immune system. Certainly, even early
stage tumours have evaded immune control, suggesting that
they have acquired many immunosuppressive characteris-
tics (Lu and Fink, 2008). Depression of cellular immunity
could be observed at various stages of cancer and the abso-
lute count of lymphocytes in peripheral blood could be the
first and simple indicator of the immune system insuffi-
ciency. Therefore, we also look for our patients groups with
different lymphocyte absolute counts. We found out, that GI
patients with Ly (< 1.4 × 103) and latent and active infec-
tion had suppressed inductor phase of cellular immune re-
sponse and tendency to weaken humoral immune reactions.
Many studies have described beta-herpes virus ability to
suppress T cell proliferation, to induce apoptosis of CD4+ T
Ly, to alter the expression of some immune activation
markers and to perturb the cytokine network (Peng et al.,
2000; Dockrell, 2003; De Bolle et al., 2005). It has been ob-
served that CD4+ T cells from HHV-6-infected individuals
exert suppressive activity on the proliferation of native T
cells (Wang et al., 2006). The authors hypothesised that the
suppressive capacity of these CD4+ T cells could be attrib-
uted to a high population of CD4+25+ T regulatory cells,
which could be actively suppressing the immune response.
Our data show that patients with latent infection had ele-
vated CD 25+ cell absolute count, in comparison with nega-
tive and active infected patients. It is difficult to speculate
on the role of CD 25+ in our case, as these changes are not
so remarkable.
Saff et al. (2004) suggested that Fas (CD95+) or Fas-ligand
(CD95-L+) deficient tumour-specific Th1 cells survive
better in tumour-bearing mice. Moreover, these tumour-
specific Th1 cells were more effective than wild-type Th1
cells at eliminating tumours. This implies that Fas-mediated
activation-induced cell death could be a limiting factor in
effective T-cell-mediated immunosurveilance and immune
response. Our HHV-infected patients had a tendency to in-
crease Fas cell absolute count. We could suggest that such
activation may lead to cell immunocompetent cell apoptosis
and immune response functional inability. According to
some reports, NK cells could be involved in host-virus in-
teraction by different manner: NK could be infected by
beta-herpes viruses and probably change their functional ac-
tivity as well as T cells (Kruger, 1990; Clark, 2002; Migake
et al., 2006), and beta-herpes viruses could increase NK cell
activity via the cytokine network (Atedroe et al.,1997). Our
patients did not show difference in CD16 absolute count.
Lymphopenic patients with latent and active HHV-6,
HHV-7 infection had decreased mean CD16+ absolute
count in comparison with patients who were free from in-
fection. We speculate that CD 16+ cells were deleted (or
they were infected).
There were some attempts to find relationships between
beta-herpes virus infections and carcinogenesis based on
observations that HHV-6 can directly infect CD4+ cells and
induce apoptosis in immunocompetent cells, and that the vi-
rus can also infect thymic epithelial cells, hematopoietic
stem cells and NK cells which are very important for im-
mune maturation and protection against cancer and viral in-
fections. Thus, HHV-6 infection may contribute to cancer
circuitously through immune suppression (Kruger et at.,
1990). Later studies were focussed on virus-induced
immunosuppression or virus influence on the immune sys-
tem of imnosuppressed patients. Gastrointestinal malign-
ances are associated with a compromised immune system
and viruses may be able to utilise cellular mechanisms re-
sponsible for immune response inhibition. Our findings
show that patients who are compromised (lymphopenic) and
had HHV-6, HHV-7 infection had greater immune response
deviations than patients who are not immunocompromised.
Virus-mediated immune response inhibition seems to be
similar with cancer mediated. The study combining both vi-
rus- and cancer-mediated immune suppressive mechanisms
will help us to understand complicated host-tumour interac-
tions in vivo.
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ÐÛNU IMUNITÂTE AR HHV-6 UN HHV-7 INFICÇTIEM ZARNU TRAKTA VÇÞA PACIENTIEM
Cilvçka herpes vîrusus konstatç cilvçkiem ar kompromitçtu imûno atbildi. Herpes vîrusi spçj inficçt daþâdas ðûnas, ietekmçjot gan ðûnu,
gan humorâlo imunatbildi. HHV-6 un HHV-7 vîrusi spçj inficçt CD4 + T limfocîtus, kâ arî inficçt monocîtus, makrofâgus, naturâlos
killerus, epitçlija, endotçlija, nervu ðûnas un fibroblastus. Patologu noteiktâ audzçja stadija ne vienmçr saskan ar imûnas sistçmas atbildes
spçju, un jau agrînâs stadijâs audzçjs spçj pats radît imûnsupresîvu vidi. Darba mçríis bija noskaidrot  herpes vîrusu ietekmi uz ðûnu
imûno atbildi. 95 kuòìa zarnu trakta vçþa pacientiem noteicâm CD3, CD4, CD8, CD19, CD38, CD95, CD25 absolûto ðûnu lîmeni,
izmantojot lâzera plûsmas citoflorometrijas metodi. HHV-6, HHV-7 vîrusu klâtbûtni noteicâm ar nPCR metodi. Pacientiem ar negatîvu,
latentu, aktîvu HHV-6, HHV-7 infekciju nekonstatçjâm statistiski ticamu diferenci noteikto imûnkompetento ðûnu lîmenî. Pacientiem ar
kompromitçtu imûno atbildi konstatçjâm zemâku CD4, CD19 absolûto skaitu. Audzçja mediçtâ imûnâ atbilde ir lîdzvçrtîga imûnatbildei
pacientiem ar HHV-6, HHV-7 aktîvu infekciju un limpopçniju. Viena tipa (latenta, aktîva pasîva) HHV-6, HHV-7 infekcijas pacientiem
grupas robeþâs varam konstatçt atðíirîgu imûnatbildi katram indivîdam, taèu tas neietekmç grupas vidçjos râdîtâjus. Tâpçc uzskatâm, ka ir
nepiecieðams izvçrtçt imûnatbildi katram pacientam individuâli.
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